Bicycle Therapeutics plc Deferred Revenue Recognized
Bicycle Therapeutics plc (BCYC) reported Deferred Revenue Recognized of $1.27 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2020-11-05
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for the quarter ending 2020-09-30 was $1.27M, a 632.37% increase year-over-year.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for the quarter ending 2020-06-30 was $1.25M, a 1007.08% increase year-over-year.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $1.13M, a 82.32% decline year-over-year.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for the quarter ending 2019-09-30 was $173.00K, a 84.57% decline year-over-year.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2019 was $10.41M, a 132.85% increase from fiscal 2018.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2018 was $4.47M, a 1159.72% increase from fiscal 2017.
- Bicycle Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2017 was $355.00K.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2020-09-30 | $1.27M 10-Q · filed 2020-11-05 | $3.50M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $1.25M 10-Q · filed 2020-08-05 | $2.00M 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $1.13M 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $10.41M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $173.00K 10-Q · filed 2020-11-05 | $5.60M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $113.00K 10-Q · filed 2020-08-05 | $5.42M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $6.38M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $4.47M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $1.12M 10-Q · filed 2019-11-07 | $3.41M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $1.17M 10-Q · filed 2019-08-08 | $2.29M 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $355.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |